Cierra, Inc. Reports First Successful ''Non-Implant'' Cardiac Catheter PFO Closure
10/19/2005 5:13:05 PM
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 18, 2005--Cierra, Inc. announces the successful treatment of the first set of patients with their groundbreaking PFX(TM) Closure System for the treatment and closure of Patent Foramen Ovale (PFO). The Cierra PFX(TM) system is the first catheter based treatment in the world to close PFO without leaving behind a permanent implant.
A PFO is a valve-like opening between the right and left atrial chambers of the heart which usually closes shortly after birth. This opening persists into adulthood in approximately 25 percent of the population. PFO are believed to allow blood clots, which would normally be filtered by circulation through the lungs, to cause stroke, paradoxical embolization, or Transient Ischemic Attacks (TIA). PFO are one of the leading causes of stroke in young patients and have also been linked to migraine headaches.
comments powered by